Omeros Corporation's Insightful Presentations at Upcoming Meetings
Omeros Corporation (NASDAQ: OMER) is poised to showcase significant advancements in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) through its innovative drug, Narsoplimab. At the forthcoming 2025 Tandem Meetings, scheduled for mid-February in Honolulu, Omeros will feature two key presentations that highlight the real-world results of this treatment under an expanded access program.
Presenting Real-World Outcomes from Narsoplimab Treatment
Both presentations serve as a vital platform to share insights into how Narsoplimab, a fully human monoclonal antibody, is making a substantial difference in the lives of patients suffering from TA-TMA, which is a severe and often fatal condition resulting from stem cell transplants. The first presentation will offer crucial data on the overall survival rates of 128 transplant patients treated under the expanded access program, illuminating the promising effects of this treatment.
Podium Presentation by Michelle Schoettler, M.D.
During an oral abstract session on February 13, Dr. Michelle Schoettler, a distinguished Assistant Professor at Emory University School of Medicine, will present the findings of the survival rates post-treatment. This analysis is significant as it not only highlights the potential benefits of Narsoplimab but also contributes to the broader understanding of TA-TMA outcomes compared to standard care options.
Poster Presentation by Piyatida Chumnumsiriwath, M.D.
The second presentation will be led by Dr. Piyatida Chumnumsiriwath from the University of California, Irvine, where they will discuss the experiences of adult patients receiving Narsoplimab after ineffective treatment with eculizumab. This poster session will delve into the specific challenges and outcomes of this group of patients, providing further context to the necessity and effectiveness of Narsoplimab.
Key Presentation Details
The details of the presentations are already listed on the Tandem Meetings website, making them accessible for further information and context. For those interested in attending, the presentations are set to cover:
- Narsoplimab Treatment for Hematopoietic Cell Transplant Associated Thrombotic Microangiopathy - Date: February 13, 2025
Time: 3:15-3:30 p.m. HST
Location: Ballroom A (HCC) - Narsoplimab for Refractory Transplantation-Associated Thrombotic Microangiopathy - Date: February 13, 2025
Time: 6:45-7:45 p.m. HST
Location: Exhibit Hall 3 (HCC)
About Narsoplimab and Its Importance
Narsoplimab, also known as OMS721, represents a groundbreaking therapeutic option for patients suffering from TA-TMA. This investigational drug targets mannan-binding lectin-associated serine protease-2 (MASP-2), enhancing the body's natural immune response while sparing the classical complement pathway crucial for fighting infections. Currently, the FDA has granted breakthrough therapy and orphan drug designations for Narsoplimab, underscoring its potential significance in treating TA-TMA.
Understanding Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
This complex disorder illustrates a severe side effect of stem cell transplants, where damage to endothelial cells leads to various life-threatening complications. Understanding the pathology of TA-TMA is key for developing effective therapeutics like Narsoplimab. The condition's high mortality rate points to a need for innovative treatment options, as existing therapies have not been effective for many patients.
Omeros Corporation: A Leader in Innovative Biopharmaceuticals
Omeros significantly influences the biopharmaceutical landscape by focusing on innovative solutions for unmet medical needs, especially in immunologic and hematologic disorders. With ongoing developments in their pipeline, including clinical trials for their MASP-2 inhibitor, Omeros is committed to improving health outcomes for patients across various indications encompassing cancers and other severe conditions.
Frequently Asked Questions
What is Narsoplimab?
Narsoplimab is an investigational drug targeting MASP-2, designed to treat TA-TMA by modulating the immune response.
Where will the presentations take place?
The presentations will occur at the 2025 Tandem Meetings in Honolulu from February 12-15, 2025.
Who will be presenting the findings?
Dr. Michelle Schoettler and Dr. Piyatida Chumnumsiriwath will present the findings on Narsoplimab's effectiveness in treating TA-TMA.
Is there any approved therapy for TA-TMA?
No, currently there is no approved therapy or standard care specifically for TA-TMA, making research like this crucial.
What recognition has Narsoplimab received from regulatory bodies?
The FDA has granted both breakthrough therapy and orphan drug designations to Narsoplimab for treating TA-TMA.
